Tosca Melissa 4

What Happened

• Melissa Tosca, Chief Financial Officer of Kiora Pharmaceuticals (KPRX), received equity awards on 2026-03-06: 6,533 restricted shares (award) and an option/derivative covering 13,067 shares. Both grants show $0.00 per share at grant (no cash paid at grant).

Key Details

• Transaction date: March 6, 2026. Filing date (Form 4): March 10, 2026 (filed within applicable reporting window for a March 6 transaction).
• Price: $0.00 per share reported for both the restricted stock and the derivative grant.
• Shares acquired: 6,533 restricted shares (direct award); 13,067-share option/derivative.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes / vesting:
  • F1: Restricted stock vests one-third on each of April 1, 2027; April 1, 2028; and April 1, 2029, subject to continuous service.
  • F2: Option becomes exercisable one-third on April 1, 2027; remaining balance vests monthly on the first day of each month over the following two years, subject to continuous service.
• Transaction code: A = Award/Grant.

Context

• These are time-based equity grants, not open-market purchases or sales. The option/derivative is a future right to buy shares per the vesting schedule; there is no immediate exercise or sale reported. Such awards are common as compensation and align pay with future service and company performance; they do not by themselves indicate insider buying or selling intent.